Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
Rein S, Lodi S, Logan R, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein M, Young J, Jarrin I, Monforte A, Tavelli A, Meyer L, Tran L, Gill M, Lang R, Surial B, Haas A, Justice A, Rentsch C, Phillips A, Sabin C, Miro J, Trickey A, Ingle S, Sterne J, Hernán M, Collaboration A. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. The Lancet HIV 2023, 10: e723-e732. PMID: 37923486, PMCID: PMC10695103, DOI: 10.1016/s2352-3018(23)00233-3.Peer-Reviewed Original ResearchConceptsART-experienced individualsCardiovascular eventsTarget trialsART regimensRisk ratioTreatment strategiesRisk differenceEligibility criteriaIntegrase strand transfer inhibitor useAntiretroviral Therapy Cohort CollaborationIntegrase strand transfer inhibitorsPooled logistic modelART-naive individualsHIV RNA measurementsHIV-CAUSAL CollaborationNational InstituteStrand transfer inhibitorsLogistic regression modelsART regimenCohort CollaborationAntiretroviral therapyInhibitor useBlood pressureINSTI useClinical dataTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients